Klivira
Request demo

Optimizing Soliris Prior Authorization for Gastroenterology

Navigating **Soliris prior authorization for gastroenterology** practices presents unique administrative complexities, demanding a robust solution for efficient patient access to critical therapies.

Gastroenterology practices face a substantial prior authorization burden, especially with high-cost biologics and specialty drugs. While Soliris is typically associated with rare systemic conditions, its high-volume PA status means any practice, including GI, may encounter its authorization requirements. Klivira provides a specialized platform to manage these complex prior authorizations, ensuring compliance with payer policies and reducing workflow disruptions.

The Dual Challenge: Soliris PA and Gastroenterology Workflows

Soliris (eculizumab) is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, known for its stringent documentation requirements. Concurrently, gastroenterology practices manage a significant PA load from biologics for IBD, advanced imaging, and specialty GI drugs. The intersection demands a system capable of handling both the specific administrative hurdles of drugs like Soliris and the diverse PA landscape of GI.

Key Prior Authorization Triggers in Gastroenterology

  • IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors, JAK inhibitors, S1P modulators, risankizumab for Crohn's)
  • Hepatitis C direct-acting antivirals (DAAs) like sofosbuvir-velpatasvir and glecaprevir-pibrentasvir
  • Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
  • Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy, ERCP, EUS)
  • Specialty drugs for functional GI disorders (e.g., eluxadoline, prucalopride, linaclotide)
  • Non-routine colonoscopy screening exceptions

Documentation Imperatives for Complex Drug PAs in GI

For any high-cost, high-PA drug like Soliris, comprehensive documentation is non-negotiable. Within gastroenterology, this principle extends to IBD biologics, requiring diagnosis confirmation, disease severity assessment (Mayo score, CDAI), prior conventional-therapy trials, and relevant screenings. Klivira's platform is designed to capture and organize these extensive data points, regardless of the specific drug or indication, streamlining the submission process.

Common Prior Authorization Denial Factors in Gastroenterology

  • Step therapy non-compliance for IBD biologics (e.g., required failure of conventional therapy or TNF before non-TNF agents)
  • Biosimilar substitution mandates not followed for brand TNF inhibitors
  • Insufficient documentation of disease severity (e.g., missing Mayo score or CDAI)
  • Missing pre-treatment screening documentation (e.g., TB, hepatitis for biologics)
  • Fibrosis-stage or drug-drug interaction documentation gaps for Hep C DAAs
  • Inappropriate-use criteria for advanced imaging or capsule endoscopy

Klivira's Role in Streamlining Prior Authorization for GI Practices

Klivira integrates with existing EMR systems to automate data extraction for prior authorization requests, including those for complex medications like Soliris or high-volume GI biologics. Our platform applies ACG/AGA-guideline-aware logic for IBD biologic sequencing, automates treatment-status classification from EMR medication history, and manages periodic re-authorization workflows for chronic treatments. This holistic approach reduces manual effort and accelerates approval times across the diverse needs of a gastroenterology practice.

Navigating Medical vs. Pharmacy Benefit for GI Biologics

A common workflow constraint in gastroenterology, mirroring other specialties like rheumatology, is the split between medical and pharmacy benefits for biologic agents. Provider-administered infusions fall under the medical benefit, while self-administered injections are typically pharmacy benefit. Klivira's logic engine is equipped to route requests appropriately, adapting as a patient's administration mode or payer policy changes, ensuring accurate submission for drugs whether they are administered in-office or self-administered.

Frequently asked questions

How does Klivira handle the documentation requirements for a high-cost drug like Soliris within a GI practice?

Klivira's platform extracts relevant patient data from your EMR, compiling the extensive clinical evidence required for high-cost drug prior authorizations. For drugs like Soliris, this includes consolidating diagnosis codes, lab results, and treatment history, ensuring all necessary information is presented to payers, minimizing manual data entry and potential errors.

What specific GI conditions does Klivira's platform support for prior authorization automation?

Klivira supports prior authorizations across the full spectrum of gastroenterology, including IBD biologics, Hepatitis C DAAs, advanced imaging, and endoscopic procedures. Our system incorporates ACG/AGA-guideline-aware logic to streamline approvals for conditions like Crohn's disease, ulcerative colitis, and chronic hepatitis.

How does Klivira address step therapy requirements common in GI prior authorizations?

Klivira's intelligent logic engine incorporates payer-specific step therapy protocols for GI biologics. It identifies if conventional therapies or biosimilars must be tried first, guiding your team to provide the necessary documentation or flags potential denials based on non-compliance, ensuring adherence to payer policy.

Can Klivira manage re-authorizations for chronic GI conditions like IBD?

Yes, Klivira automates the periodic re-authorization workflow essential for chronic treatments in gastroenterology, such as IBD biologics. The platform tracks re-authorization cadences, proactively alerts your team, and pre-populates forms with updated clinical information to ensure continuous patient access to critical therapies.

How does Klivira differentiate between medical and pharmacy benefit for GI biologics?

Klivira's system is designed to identify and correctly route prior authorization requests based on whether a biologic is provider-administered (medical benefit) or self-administered (pharmacy benefit). This distinction is critical for accurate submission and avoids delays or denials stemming from misclassification of the benefit type.

Related coverage

Other soliris prior authorization by payer

Other soliris prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo